HENGRUI PHARMA(01276.HK): HRS-3005 Tablets Granted Clinical Trial Approval for B-Cell Malignancies
NewTimeSpace News: Jiangsu Hengrui Pharmaceutical Co., Ltd. (01276.HK) released an overseas regulatory announcement on May 8, 2026, stating that the Company has received the Notice of Approval for Clinical Trials for HRS-3005 Tablets issued by the National Medical Products Administration (NMPA), and will conduct clinical trials in the near future.
The acceptance numbers are CXHL2600130 and CXHL2600131. The approval conclusion is to 同意开展临床试验 for B-cell malignancies.
HRS-3005 Tablets are an innovative anti-tumor drug independently developed by the Company, intended for the treatment of B-cell malignancies. According to public information, no similar drugs have been approved for marketing at home and abroad as of now.
As of the present date, the accumulated R&D investment related to the HRS-3005 Tablet project amounts to approximately RMB 26.2 million (unaudited).
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- HENGRUI PHARMA (01276.HK): Two Drugs Win Clinical Trial Approval in China
- HENGRUI PHARMA (01276.HK): SHR-4595 Gets Clinical Trial Approval in China
- HENGRUI PHARMA (01276.HK): Makes A-Share Repurchase of 335,000 Shares for RMB 14,503,550
- HENGRUI PHARMA (01276.HK): HRS-4139 Tablets Cleared for Clinical Trial in Moderate-to-Severe Plaque Psoriasis
- HENGRUI PHARMA (01276.HK): Recaticimab Cleared for Clinical Trials, Phase III Study Planned in Stroke Recurrence
